



ENTHEON

A NEW DIMENSION IN ADDICTION TREATMENT

CORPORATE PRESENTATION

MARCH 2022

CSE:ENBI | OTCQB:ENTBF | FSE:1XU1

DISCLAIMER

This presentation of Entheon Biomedical Inc. (the "Company") is for information only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities. It has been provided solely to assist the recipient in evaluating the Company. This presentation is not, nor is it to be construed under any circumstances as a prospectus, a public offering of securities, or an offering memorandum as defined under any applicable securities legislation. The presentation does not contain all of the information that would normally appear in an offering registered under applicable securities laws.

This presentation should not be construed as legal, financial or tax advice to any individual, as each individual's circumstances are different. Readers should consult with their own professional advisors regarding their particular circumstances. The information contained in this presentation is not directed to persons or entities resident in the United States and does not constitute an offer or solicitation by anyone in the United States or in any other jurisdiction in which such an offer or solicitation is not authorized or to any person to whom it is unlawful to make such an offer or solicitation, unless otherwise exempt from United States securities legislation.

FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein including, without limitation, statements with respect to the proposed research and development programs to be conducted by the Company, the Company's plans to develop treatments and products for addiction, the effect the psychedelic treatments and

products will have on substance use disorders and other related conditions, potential DMT indications, the identification of additional useful biomarkers, the projected clinical trial timeline, the Company's partnerships, including with subsidiaries HaluGen Life Sciences Inc. and Lobo Genetics Inc., and the anticipated business plans regarding the foregoing, the timing of future activities and future business, economic and market conditions and growth are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: "believes", "expects", "anticipates", "intends", "estimates", "plans", "potential", "projects", "scheduled", "may", "could", "should", "would", "will" or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved.

In making the forward-looking statements in this presentation, the Company has applied several material assumptions, including without limitation, assumptions relating to the expected market growth, results and efficacy of clinical studies, performance, industry trends, market opportunities, that the Company will be able to complete its propose research and development plans and develop treatments for addiction and related conditions, the expected benefits and impact of psychedelic treatments, the timeline and success of clinical trials, the receipt of all required regulatory approvals, that the Company will be able to obtain the financing required to carry out its planned future activities, the ability to retain and attract qualified personnel and obtain and/or maintain the necessary rights, patents or permits it needs to carry out its future business activities. While the Company considers these assumptions to be

reasonable, the assumptions are inherently subject to significant business, social, economic, political, regulatory, competitive and other risks and uncertainties, contingencies and other factors that could cause actual actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking information. Many assumptions are based on factors and events that are not within the control of the Company and there is no assurance they will prove to be correct.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks, uncertainties and other factors include, among others, any inability to obtain and maintain all necessary governmental approvals licenses and permits to complete the Company's research and development programs and business as planned; the acceptance of the Company's patent applications and the granting of the patents thereunder; regulatory or political change such as changes in applicable laws and regulations, including federal, state and provincial legalization, due to inconsistent public opinion and perception of the psychedelic industry, bureaucratic delays or inefficiencies or any other reasons; the risk of engaging in activities which are considered to be illegal under Canadian, United States or international law; any other factors or developments which may hinder market growth; the Company's limited operating history and lack of revenue; reliance on management; the Company's requirements for additional financing and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; the need to secure and maintain corporate alliances and partnerships; and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated June 24, 2021 available on the Company's profile at www.sedar.com. This is not an exhaustive list of the risks and factors that may affect the forward-looking statements contained herein. Although the Company has attempted to identify important factors that could affect the Company and may cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in the forward-looking statements, there may be other factors that cause actions, events, conditions, results, performance or achievements not to be as anticipated, estimated or intended.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update any of the forward-looking statements in this presentation or incorporated by reference herein, except as otherwise required by law.

DISCLAIMER REGARDING SCHEDULE I CONTROLLED SUBSTANCES


Psychedelics, like DMT, MDMA and Ketamine, are currently Schedule I controlled substances under the Federal Controlled Substances Act of 1970. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of accepted safety for the use of the drug under medical supervision. As such, the manufacture, importation, possession, use or distribution of psychedelics is illegal under U.S. law. There can be no assurance that the U.S. government or its agencies will accept or approve psychedelics for medical purposes.

© ENTHEON HOLDINGS CORP. 2021 | ALL RIGHTS RESERVED

STRATEGIC PILLARS



Entheon is powered by an unwavering commitment to significantly improve the odds of beating addiction and improving patient care.



Entheon RX™- focusing on the development of drugs, using DMT as the pharmacological benchmark



Entheon ID™ - focusing on the identification, analysis and predictive use of genetics and EEG biomarkers in the selection and management of drug treatment



Entheon IQ™ - development of treatment algorithms through the analysis of patient data



OUR TEAM



Timothy Ko
CHIEF EXECUTIVE OFFICER

Broad background of leading private ventures in different sectors



Andrew Hogle, PhD
CHIEF SCIENCE OFFICER

Adjunct Professor of Pharmacology at the University of British Columbia



Brian Jahns, PharmD
CHIEF BUSINESS OFFICER

20+ years of biopharmaceutical industry experience



Brandon Schwabe CPA, CGA
CHIEF FINANCIAL OFFICER

A decade of professional experience in finance and accounting



Yaron Eshel
PROJECT MANAGER

Has led clinical trials and worked with CRO's all over the world




Christopher Gondi Ph.D., M.Sc.
BOARD MEMBER

Depts. Of Medicine, Surgery and Pathology at the University of Illinois



Ruth Chun M.A., J.D.
BOARD MEMBER

Corporate commercial lawyer with expertise in regulated industries



SCIENTIFIC ADVISORY BOARD



Matthew W. Johnson

Ph.D.

Professor of Psychiatry and Behavioral Sciences, Johns Hopkins



Robin Carhart-Harris

Ph.D.

Founding Director of the UCSF Neuroscape Psychedelics Division



Dr. Andrew Greenshaw

Ph.D.

Professor / Assoc Chair
Department of Psychiatry, U of A



Dr. David Erritzoe

Ph.D., MD

Senior Lecturer in Psychiatry in Centres for Neuropsychopharmacology and Psychedelic Research at Imperial College, London



Dennis McKenna

Ph.D.

Ethno-pharmacologist, pharmacognosist, lecturer and author



Christopher Timmerman

Ph.D.

Lead Researcher, The Psychedelic Research Group, Imperial College, London



Dr. Michael Walker

Ph.D.

Prof. Emeritus Anesthesiology, Pharmacology and Therapeutics, UBC



Nancy Maher

Special Advisor

Technology & pharma industry veteran specializing in data and regulatory affairs



Entheon is advancing DMT research in the field of addiction medicine

Clinically evaluating DMT as an addiction treatment through our EBRX-101 Phase 1 Human Trial, currently in progress, the most rigorous and comprehensive study of DMT to date

In pursuing this study, Entheon seeks to:

- Leverage DMT's pharmacokinetics for a flexible therapeutic program
- Optimize dosage and duration of treatment to suit patient needs

Entheon seeks to develop a personalized medicine platform that leverages genetics and EEG data to:

Predict mental health risks and characterize metabolic factors linked to treatment outcome

Aid in drug selection and personalization of therapy

Applicable to a variety of psychedelic molecules and indications


Investigation of DMT-based NCEs with medicinal chemistry partners

Researching Proprietary DMT-delivery systems



OUR MOLECULE OF FOCUS

DMT elicits the desirable entropic effects of classic psychedelics but has unique pharmacokinetic qualities that make it a promising molecule for clinical use.



N,N-Dimethyltryptamine (DMT)

DMT'S DIFFERENTIATING QUALITIES⁶



+ + + + + + + +

Increased activation of 5HT2A receptors compared to other psychedelics

EC50 (potency) = 0.08 micromolar for DMT (vs 0.7 micromolar for psilocybin)

% maximum activation of 5HT2A is 2-fold higher with DMT over psilocybin

Rapid pharmacokinetics compared to other psychedelics

T1/2 = 5 min for DMT (vs 50 min for psilocybin)

Allows for near-real-time clearance of drug effects when infusion is stopped

Enhanced neural plasticity and neurogenesis

DMT increases dendritic spine density and synapse formation

Stimulates production of new hippocampal neurons

Neuroprotective effects via sigma-1 receptor activation

DMT is anti-inflammatory and anti-ischemic



THE DMT MOLECULE

DMT possesses significant therapeutic advantages over classic psychedelics



Ayahuasca, Psilocybin & LSD

- + Long duration (6-8hrs)
- + Difficult to scale commercially
- + Limited means of ending a negative adverse reaction
- + Lack of precise dose control

DMT

- + Shorter session length (30-60mins)
- + Higher patient throughput
- + Ability to end session quickly if clinically necessary
- + Titrate/modify dose if required
- + Flexible therapeutic design
- + Potentially less time needed in psychedelic state

SIGNIFICANT UNMET NEED

“21.2 million Americans have a substance use disorder. In 2018, just 11% of those patients received the treatment they needed.”

- Association of American Medical Colleges

A GROWING COST

“The estimated cost of drug abuse in the United States—including illegal drugs, alcohol, and tobacco—is more than \$740 billion a year and growing...”

- National Institute on Drug Abuse

100,306

Overdose deaths in the United States between May 2020 and April 2021

- The CDC

11.8M

Estimated deaths, worldwide, in 2017 from alcohol, tobacco and illicit drug-use¹

- The Lancet



“The psychedelic drugs market is projected to grow at a CAGR of 12.36% over the next eight years, to reach **\$10.75 billion by 2027.**”

- 2020 Research & Markets Report

HISTORICAL EVIDENCE FOR PSYCHEDELICS IN TREATMENT OF ADDICTION



Serotonergic psychedelics have a robust history of research related to addiction treatment.

LSD Alcoholism

In 2012 a meta-analysis of LSD use in the treatment of alcoholism was published that showed 58% improvement at first follow up, vs. 38% of controls.¹

Ayahuasca Alcoholism



Ayahuasca demonstrated a reduction in severity of alcoholism.¹

Psilocybin Smoking

Psilocybin for the treatment of smoking cessation resulted in 87% abstinence at 6 months, 67% at 12, 60% at 16. 87% report being among 5 most meaningful experiences of their lives.¹



FROM PATHOLOGICAL TO PIVOTAL STATE CHANGE





ENTHEON

Our progress

PROJECTED R&D TIMELINE 1



EBIQ-101 Observational EEG Study

NCE Patent Submission
Alternate route of administration feasibility study (Optional)

◀ Q3 21 • Q4 21 • Q1 22 • Q2 22 • Q3 22 • Q4 22 • 2023+ ▶

In-Vivo Pre-Clinical Study

EBRX-101 Human Trial

Proposed Phase 2 Nicotine

Subjective State EEG Patent Submission

Proposed Phase 2 Alcohol

EBRX-101 Phase 1 Clinical Trial

Phase 1/2a study at Centre for Human Drug Research (Leiden, Netherlands) using healthy nicotine-addicted volunteers.

Location

CHDR, Leiden, Netherlands

Start Date

Q1 of 2022

Objective

Primary aim is to assess PK/PD and safety pharmacology, will also obtain EEG and genetic data

Estimated study completion

Second-half of 2022

Nonclinical Studies Completed

In support of anticipated FDA engagement

Complete: In vitro toxicity and cardiac safety studies

Location: CRO #1, Israel

In vivo intravenous toxicity assay

Location: CRO #1, Israel

In vivo assays in rats examining the effect of DMT on a binge drinking model

Location: CRO #2, Israel

NCE Program

DMT-based molecular entities evaluated on docking, binding and ease of synthesis

- ✓ Exhaustive literature search complete
- Evaluating synthesis partners

Desired properties:

Neurogenerative/anti-ischemic
Non-hallucinatory
Enhanced pharmacokinetics

Expected filings:

DMT-based molecular entities
Targeting first-half of 2022

Routes of Administration R&D

Evaluation in progress for routes of administration to service specific indications

- ✓ Development partner identified
- ✓ Dose ranges selected

Feasibility study

EBIQ-101 Observational Study

Effect of Ketamine on Neurological Activity as Measured by Electroencephalogram (EEG)

Location

Heading Health, Austin – TX

Status

Active

Objective

Correlation of neurological phenotypes with genetic markers

Study will focus on treatment-resistant Major Depressive Disorder (MDD) Track/metricize positive effects

Data will contribute to the design of future studies utilizing Ketamine for various psychiatric disorders

Estimated study completion

Q3 of 2022

DMT Biomarker Program

Effect of DMT on Neurological Activity at various dose ranges as Measured by Electroencephalogram (EEG). This study will be occurring in tandem with EBRX-101.

Location

CHDR, Leiden, Netherlands

Status

Active

Estimated study completion:

Second-half of 2022

Commercially available genetic test kits related to psychedelic drugs and cannabis

Fully-functional research and analytics facility

Test kits highlight genetic markers potentially associated with mental health risks and metabolism associated with psychedelics, THC and CBD.

Currently being expanded to include additional biomarkers

Highly-accredited genetics research team



HalUGen key genotypes

HTR2A
Sensitivity to serotonergic psychedelics

CYP2B6
Ketamine metabolism

CYP2D6*
DMT/LSD/MDMA metabolism

Key genetic markers

C4A NRG1 DISC1 HTR1A*

Near & long-term risk factors (e.g., psychosis & schizophrenia)



Lobo key genotypes

+ **CYP2C9**
THC metabolism

+ **CYP2C19**
CBD metabolism

Key genetic markers

AKT1 COMT

Near & long-term risk factors related to psychosis & memory




Entheon Biomedical plans to focus on developing three strategic pillars that will aim to drive growth and create positive patient outcomes

Entheon Rx™ Molecular Development	Entheon ID™ Genetics	Entheon IQ™ Bio-markers & Treatment Algorithms
<p>Current research: EBRX-101 Phase 1 Clinical Trial - DMT safety and PK/PD study</p> <p>Novel Drug Development using DMT as the pharmacological benchmark</p> <p>DMT delivery systems</p>	<p>Current DTC genetic test (HaluGen). Five biomarkers related to psychiatric risk and metabolic factors*</p> <p>Focusing on the identification, analysis and predictive use of genetics in the selection and management of drug treatment</p> <p>Developing an expanded psychedelic panel for healthcare providers</p>	<p>Current Research: EBIQ-101 Observational Study</p> <p>Development of treatment algorithms through the analysis of patient data.</p> <p>DMT biomarker project</p> <p>Mental health phenotypes</p>

PERSONALIZED PSYCHEDELIC MEDICINE



Entheon's integrative approach to personalized medicine is seeking to change the current landscape of psychedelic psychiatry





2019

Founded

Nov. 12, 2020

Commenced trading
on the CSE

CSE: ENBI

FSE: 1XU1

OTCQB: ENTBF

Outstanding Shares 59,089,266

Fully diluted 70,812,599

Cash Position as of \$700k CAD
03/15/2022

Thank you

ENTHEON

ENTHEON BIOMEDICAL CORP.